TEANECK, N.J., June 21, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that it is partnering with Accuray Incorporated (NASDAQ: ARAY) to support the company's deployment of SAP S/4HANA to obtain better data and analytics, and achieve greater business efficiencies. Accuray develops, manufactures, and sells radiotherapy systems for the precise, personalized treatment of cancer and certain neurologic conditions. As part of a global agreement, Cognizant is providing planning, design, implementation, change management, and program management for sales, procurement, manufacturing, distribution, installation, and service processes supported by SAP S/4HANA.
The medical technology industry faces pressure to streamline processes and reduce costs while continuing to innovate and introduce new products to market more quickly. Cognizant is working with Accuray to augment its infrastructure with the resources necessary for success.
"Cognizant is a trusted partner whose assistance will help us efficiently and effectively deploy SAP across our global organization. The new Enterprise Resource Planning (ERP) system will provide a platform to streamline and optimize business processes by making available real-time intelligence and insights to inform our decision making. Our team will have the resources needed to become nimbler in the way we operate, ultimately enabling us to enhance our support of the medical professionals involved in patient care," said GS JHA, Global Chief Information Officer and Chief Information Security Officer at Accuray.
"Cognizant is dedicated to partnering with healthcare technology companies focused on the development of lifesaving products," said Surya Gummadi, EVP and President, Cognizant Americas. "We're honored Accuray, a global leader in high-tech, targeted cancer treatment, has chosen Cognizant to help drive operational changes that will enable them to more efficiently develop, deliver and service radiotherapy solutions used worldwide to improve patient care."
About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.
For more information, contact: | ||||
U.S. Name Ben Gorelick Email This email address is being protected from spambots. You need JavaScript enabled to view it. | Europe / APAC Name Christina Schneider Email This email address is being protected from spambots. You need JavaScript enabled to view it. | India Name Rashmi Vasisht Email This email address is being protected from spambots. You need JavaScript enabled to view it. | ||
| Last Trade: | US$2.15 |
| Daily Change: | 0.06 2.87 |
| Daily Volume: | 770,303 |
| Market Cap: | US$213.370M |
November 06, 2024 September 10, 2024 August 27, 2024 August 14, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
